The effect of mycophenolate mofetil on primary and secondary treatment of primary glomerulonephritis and lupus nephritis

Basit Öğe Kaydı
dc.authoridtaskapan, hulya/0000-0001-8736-4779
dc.authoridSertdemir, Yasar/0000-0003-4455-3590
dc.authorwosidtaskapan, hulya/ABI-7737-2020
dc.authorwosidPembegul, Irem/HJA-2191-2022
dc.authorwosidKURT, CEMAL/I-1828-2018
dc.authorwosidSertdemir, Yasar/E-5104-2018
dc.contributor.authorPaydas, Saime
dc.contributor.authorKurt, Cemal
dc.contributor.authorTaskapan, Hulya
dc.contributor.authorBalal, Mustafa
dc.contributor.authorSertdemir, Yasar
dc.contributor.authorPembegul, Irem
dc.date.accessioned2024-08-04T20:31:09Z
dc.date.available2024-08-04T20:31:09Z
dc.date.issued2009
dc.departmentİnönü Üniversitesien_US
dc.description.abstractMycophenolate mofetil (MMF) has shown to be a reliable choice in the treatment of glomerulonephritis. We retrospectively reviewed the clinical course and response to MMF therapy in 49 patients with primary glomerulopathy (37 patients) and lupus nephritis [class III (five patients) and IV (seven patients)]. Patients were treated with MMF for more than 6 months as a primary (18 patients) or an adjunctive treatment (31 patients). Patients were also on methylprednisolone (2-20 mg/day) and angiotensin converting enzyme inhibitor/angiotensin receptor blocker. The mean age of the patient cohort was 33.69 +/- A 12.4 years (range 19-59 years). Twenty-four-hour urinary protein excretion was reduced from 3.50 +/- A 3.08 g prior to the commencement of MMF drug therapy to 1.21 +/- A 1.44 and 0.99 +/- A 1.34 g at the sixth and 12th months of MMF therapy, respectively (P < 0.05 for all). During this same period, significant increases in serum total protein (from 5.92 +/- A 1.38 to 6.59 +/- A 0.79 and 6.81 +/- A 0.77 g/dl) and albumin levels (from 3.23 +/- A 1.10 to 3.93 +/- A 0.67 and 4.21 +/- A 0.50 g/dl) were detected, whereas total cholesterol and low-density lipoprotein levels were found to be significantly decreased (P < 0.05 for all). Serum creatinine levels did not significantly change. The efficacy of MMF in reducing proteinuria was similar in both first line and an adjunctive therapy. The efficacy of MMF therapy began at the third month of treatment and continued through to the 12th month. Mycophenolate mofetil therapy was found to be useful in achieving improvements in proteinuria and nephrotic syndrome and stabilizing renal function. It was also a well-tolerated drug by the majority of the patients. Based on our results, we suggest that MMF may be alternative therapy for resistant/relapsing primary glomerulopathies and lupus nephritis.en_US
dc.identifier.doi10.1007/s11255-008-9454-4
dc.identifier.endpage152en_US
dc.identifier.issn0301-1623
dc.identifier.issue1en_US
dc.identifier.pmid18766457en_US
dc.identifier.scopus2-s2.0-62349113109en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage145en_US
dc.identifier.urihttps://doi.org/10.1007/s11255-008-9454-4
dc.identifier.urihttps://hdl.handle.net/11616/94765
dc.identifier.volume41en_US
dc.identifier.wosWOS:000263508000022en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofInternational Urology and Nephrologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLupus nephritisen_US
dc.subjectMycophenolate mofetilen_US
dc.subjectPrimary glomerulonephritisen_US
dc.subjectProteinuriaen_US
dc.titleThe effect of mycophenolate mofetil on primary and secondary treatment of primary glomerulonephritis and lupus nephritisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu